ConfIntervalChangeValue: RESULTS : Metformin treatment prevented weight gain ( mean weight gain , - 3 . 07 kg [ range , - 3 . 85 to - 2 . 28 kg ] ; P < . 001 ) , improved glycemic control ( mean reduction in HbA ( 1c ) level , 0 . 4 % percentage point [ **95** **%** **CI** **,** **0** **.** **55** **-** **0** **.** **25** ] ; P < . 001 ) ( where CI indicates confidence interval ) , despite the aim of similar glycemic control in both groups , and reduced insulin requirements ( mean reduction , 19 . 63 IU / d [ **95** **%** **CI** **,** **24** **.** **91** **-** **14** **.** **36** IU / d ] ; P < . 001 ) .
CTDesign: AIMS / HYPOTHESIS : This 52 - week multinational , randomised , open - label , parallel - group , **non** **-** **inferiority** trial compared clinical outcomes following supplementation of oral glucose - lowering drugs with basal insulin analogues detemir and glargine in type 2 diabetic patients .
Journal: **Clin** **Ther** **.**
SdDevChangeValue: MAGE decreased from baseline in both the vildagliptin ( - 13 . 4 ± **35** **.** **7** mg / dL ) and sitagliptin ( - 8 . 4 ± **24** **.** **3** mg / dL ) groups , but neither within - nor between - group changes were statistically significant .
PValueChangeValue: Significant reductions in fasting serum proinsulin levels and the proinsulin / insulin ratio were seen with sitagliptin treatment compared with placebo ( both , **P** **<** **0** **.** **01** ) .
Author: **Rosenstock** **J** ( 1 ) , **Brazg** **R** , **Andryuk** **PJ** , **Lu** **K** , **Stein** **P** ; Sitagliptin Study 019 Group .
SubGroupDescription: RESULTS : There was a clinically relevant decrease in glycosylated haemoglobin ( GHb ) values from baseline to endpoint with both drugs ( insulin glargine : - 0 . 46 % ; NPH insulin : - 0 . 38 % ; p = 0 . 415 ) ; also , this difference was statistically significant in the subgroup of **overweight** **patients** **with** **BMI** **>** **28** **kg** **/** **m** **2** ( insulin glargine : - 0 . 42 % , NPH insulin : - 0 . 11 % ; p = 0 . 0237 ) .
SdDevBL: The mean ( SD ) baseline HbAlc value was 8 . 1 % ( **0** **.** **8** ) in the sitagliptin group and 8 . 0 % ( **0** **.** **8** ) in the placebo group .
Precondition: OBJECTIVE : The efficacy and tolerability of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy were assessed in patients with **type** **2** **diabetes** **and** **inadequate** **glycemic** **control** **(** **glycosylated** **hemoglobin** **[** **HbA** **(** **1c** **)** **]** **>** **or** **=** **7** **%** **and** **<** **or** **=** **10** **%** **)** **while** **receiving** **a** **stable** **dose** **of** **pioglitazone** .
Frequency: Patients were randomized in a 1 : 1 ratio to receive sitagliptin 100 mg **once** **daily** or placebo for 24 weeks .
PercentageAffected: Mean HbA ( 1c ) values at end point were 7 . 2 % ( 0 . 9 ) and 7 . 8 % ( 1 . 1 ) in the respective treatment groups , and the proportions of patients reaching a target HbA ( 1c ) of < 7 . 0 % were **45** **.** **4** % and **23** **.** **0** % ( P < 0 . 001 ) .
TimePoint: **After** **24** **weeks** , sitagliptin added to pioglitazone therapy was associated with significant reductions compared with placebo in HbA ( 1c ) ( between - treatment difference in least squares [ LS ] mean change from baseline .
ResultMeasuredValue: Mean HbA ( 1c ) values at end point were **7** **.** **2** % ( 0 . 9 ) and **7** **.** **8** % ( 1 . 1 ) in the respective treatment groups , and the proportions of patients reaching a target HbA ( 1c ) of < 7 . 0 % were 45 . 4 % and 23 . 0 % ( P < 0 . 001 ) .
PvalueDiff: - 0 . 70 % ; 95 % CI , - 0 . 85 to - 0 . 54 ; **P** **<** **0** **.** **001** ) and FPG ( - 17 . 7 mg / dL ; 95 % CI , - 24 . 3 to - 11 . 0 ; **P** **<** **0** **.** **001** ) .
ObjectiveDescription: OBJECTIVE : **The** **efficacy** **and** **tolerability** **of** **the** **dipeptidyl** **peptidase** **-** **4** **inhibitor** **sitagliptin** **added** **to** **ongoing** **pioglitazone** **therapy** **were** **assessed** **in** **patients** **with** **type** **2** **diabetes** **and** **inadequate** **glycemic** **control** **(** **glycosylated** **hemoglobin** **[** **HbA** **(** **1c** **)** **]** **>** **or** **=** **7** **%** **and** **<** **or** **=** **10** **%** **)** **while** **receiving** **a** **stable** **dose** **of** **pioglitazone** **.**
ConclusionComment: CONCLUSIONS : **Treatment** **with** **metformin** **for** **3** **years** **substantially** **reduced** **major** **cardiovascular** **events** **in** **a** **median** **follow** **-** **up** **of** **5** **.** **0** **years** **compared** **with** **glipizide** **.**
DoseDescription: **Doses** **were** **adjusted** **to** **obtain** **target** **fasting** **glucose** **<** **6** **.** **7** **mmol** **/** **l** **.**
Drug: RESEARCH DESIGN AND METHODS : Type 2 diabetic patients with HbA ( 1c ) ( A1C ) ( 7 - 10 % ) who were receiving the maximum tolerated sulfonylurea dose and had a contraindication to or poor tolerance of metformin were randomly assigned ( double blind ) to receive **benfluorex** 450 mg / day ( n = 165 ) or placebo ( n = 160 ) for 18 weeks .
AvgAge: A total of 304 type 2 diabetic patients with CAD , mean age = **63** **.** **3** years ( range , 36 - 80 years ) , were enrolled .
PMID: DOI : 10 . 1016 / j . clinthera . 2006 . 10 . 007 PMID : **17157112** [ Indexed for MEDLINE ]
FinalNumPatientsArm: 37 ( 27 % ) of **137** patients in the placebo group achieved their individualised targets by education and interactions with the study team alone and 72 ( 52 · 6 % ) of **137** patients achieved their target in the vildagliptin group ( adjusted odds ratio 3 · 16 , 96 · 2 % CI 1 · 81 - 5 · 52 ; p < 0 · 0001 ) .
MinAge: METHODS : This was a 24 - week , multicenter , randomized , double - blind , placebo - controlled , parallel group study in patients aged > or = **18** years ( ClinicalTrials .
AllocationRatio: Patients were randomized in a **1** **:** **1** ratio to receive sitagliptin 100 mg once daily or placebo for 24 weeks .
NumberAffected: Sitagliptin was generally well tolerated , with no increased risk of hypoglycemia compared with placebo ( **2** vs 0 patients , respectively ) .
NumberPatientsCT: A total of **304** type 2 diabetic patients with CAD , mean age = 63 . 3 years ( range , 36 - 80 years ) , were enrolled .
DoseValue: Patients were randomized in a 1 : 1 ratio to receive sitagliptin **100** mg once daily or placebo for 24 weeks .
NumberPatientsArm: RESULTS : **One** **hundred** **seventy** **-** **five** patients were randomized to receive sitagliptin , and **178** were randomized to receive placebo .
AggregationMethod: Intention - to - treat analysis showed an adjusted **hazard** **ratio** ( HR ) of 0 . 54 ( 95 % CI 0 . 30 - 0 . 90 ; P = 0 . 026 ) for the composites of cardiovascular events among the patients that received metformin , compared with glipizide .
DiffGroupAbsValue: **-** **0** **.** **70** % ; 95 % CI , - 0 . 85 to - 0 . 54 ; P < 0 . 001 ) and FPG ( **-** **17** **.** **7** mg / dL ; 95 % CI , - 24 . 3 to - 11 . 0 ; P < 0 . 001 ) .
SdDevResValue: Mean HbA ( 1c ) values at end point were 7 . 2 % ( **0** **.** **9** ) and 7 . 8 % ( **1** **.** **1** ) in the respective treatment groups , and the proportions of patients reaching a target HbA ( 1c ) of < 7 . 0 % were 45 . 4 % and 23 . 0 % ( P < 0 . 001 ) .
ObservedResult: **Significant** **reductions** in fasting serum proinsulin levels and the proinsulin / insulin ratio were seen with sitagliptin treatment compared with placebo ( both , P < 0 . 01 ) .
Title: **Efficacy** **and** **safety** **of** **the** **dipeptidyl** **peptidase** **-** **4** **inhibitor** **sitagliptin** **added** **to** **ongoing** **pioglitazone** **therapy** **in** **patients** **with** **type** **2** **diabetes** **:** **a** **24** **-** **week** **,** **multicenter** **,** **randomized** **,** **double** **-** **blind** **,** **placebo** **-** **controlled** **,** **parallel** **-** **group** **study** **.**
ConfIntervalDiff: - 0 . 70 % ; **95** **%** **CI** **,** **-** **0** **.** **85** **to** **-** **0** **.** **54** ; P < 0 . 001 ) and FPG ( - 17 . 7 mg / dL ; **95** **%** **CI** **,** **-** **24** **.** **3** **to** **-** **11** **.** **0** ; P < 0 . 001 ) .
Country: Author information : ( 1 ) Dallas Diabetes and Endocrine Center , Texas 75230 , **USA** .
RelativeChangeValue: Postintervention , the MET group had a **35** % improvement in insulin sensitivity ( WBISI ) compared with the placebo group ( p = 0 . 008 ) .
PublicationYear: **2006** Oct ; 28 ( 10 ) : 1556 - 68 .